Freya Pharma Solutions Secures Us$8.5 Million Enabling The Start Of A Pivotal Phase 3 Trial With Lybrido Against Female Sexual Interest/Arousal Disorder (Fsiad)
Amount Raised
$8.5 Million
Round Type
Funding Round
AmsterdamDescription
Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women who have been diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD), today announced to have secured US$8.5 million in new funding from existing and new investors. The new funding will be used to carry out a pivotal phase 3 trial with its therapy Lybrido in 516 patients across Europe. Previously, Lybrido showed clinical relevance and statistical significance in a phase 2b clinical trial, clearly meeting the primary endpoints. The phase 3 trial will start in the second half of 2022, with interim results expected by the second half of 2023.
Who to call at Freya Pharma Solutions, and when
A new round usually means Freya Pharma Solutions is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Freya Pharma Solutions raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Freya Pharma Solutions, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Freya Pharma Solutions. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Freya Pharma Solutions raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Freya Pharma Solutions raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.